Oncology Central

Novel immunotherapy provides potential treatment for diffuse intrinsic pontine glioma

Recently published in the Journal of Experimental Medicine, a study led by Hideho Okada (University of California, CA, USA) has identified a neoantigen present in diffuse intrinsic pontine glioma (DIPG).

“It is important to develop more innovative treatment approaches for childhood brain cancers, which now are the leading cause of cancer death in children. DIPG is a very deadly type of brain cancer, and not many children survive beyond 12 months from the time of diagnosis.” Okada explained.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.